CD274 and neoplasm: Although programmed death-ligand 1 (PD-L1) expression, tumor mutational burden (TMB), and circulating tumor DNA (ctDNA) status can predict pathological response after nICT treatment, this multi-group biomarker-based approach is costly and demonstrates limited predictive efficacy (8, 13).